| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Microbiology and Tumor Biology Center (MTC), Karolinska Institute, Stockholm, Sweden;
Max-Delbruck Center for Molecular Medicine (MDC), Berlin-Buch, Germany; and
Department of Experimental Oncology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
Tumor cells that are treated with rIL-10 or transfected with the IL-10 gene show phenotypic changes. These include low but peptide-inducible expression of MHC class I, low sensitivity to specific CTL-mediated lysis, and increased NK sensitivity. In vitro-established mouse tumor lines were screened for IL-10 expression and production, and a large proportion of plasmocytomas or T cell lymphomas were found to produce IL-10. Since one of these lines was the prototype NK target cell YAC-1, we investigated whether the high IL-10 production of this cell line was related to its high NK sensitivity and its defects in MHC class I expression. The decrease in H-2 expression following the in vitro culture of in vivo-passaged YAC-1 cells was accompanied by a gradual increase in IL-10 production, whereas the reverse was found when passing in vitro-grown YAC-1 in vivo as an ascites tumor in syngenic mice. In addition, differences in YAC-1 MHC class I expression correlated with alterations in the functional activity of TAP-1/2 proteins. YAC-1 cells that were transduced with a retroviral IL-10 antisense construct (Y-IL-10 AS) only produced about half of the IL-10 that was produced by YAC-1 transduced with the control construct (Y-IL-10 Mock). Relative to Y-IL-10 Mock cells, the expression of H-2 on Y-IL-10 AS cells was markedly increased, and NK sensitivity was decreased. These data argue for a mechanism wherein IL-10 production is causally related to the low H-2 expression, decreased TAP function, and high NK sensitivity of YAC-1 cells.
This article has been cited by other articles:
|
|
 |
|
  H. Norell, M. Carlsten, T. Ohlum, K.-J. Malmberg, G. Masucci, K. Schedvins, W. Altermann, D. Handke, D. Atkins, B. Seliger, et al. Frequent Loss of HLA-A2 Expression in Metastasizing Ovarian Carcinomas Associated with Genomic Haplotype Loss and HLA-A2-Restricted HER-2/neu-Specific Immunity. Cancer Res., June 15, 2006; 66(12): 6387 - 6394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mocellin, F. M. Marincola, and H. A. Young Interleukin-10 and the immune response against cancer: a counterpoint J. Leukoc. Biol., November 1, 2005; 78(5): 1043 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kurte, M. Lopez, A. Aguirre, A. Escobar, J. C. Aguillon, J. Charo, C. G. Larsen, R. Kiessling, and F. Salazar-Onfray A Synthetic Peptide Homologous to Functional Domain of Human IL-10 Down-Regulates Expression of MHC Class I and Transporter Associated with Antigen Processing 1/2 in Human Melanoma Cells J. Immunol., August 1, 2004; 173(3): 1731 - 1737. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Fujimoto, Y. Nakagawa, K. Ohara, and H. Takahashi Polyriboinosinic polyribocytidylic acid [poly(I:C)]/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes Int. Immunol., January 1, 2004; 16(1): 55 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Boyle and J. S. Hill Gaston Breaking the rules: the unconventional recognition of HLA-B27 by CD4+ T lymphocytes as an insight into the pathogenesis of the spondyloarthropathies Rheumatology, March 1, 2003; 42(3): 404 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ibe, Z. Qin, T. Schuler, S. Preiss, and T. Blankenstein Tumor Rejection by Disturbing Tumor Stroma Cell Interactions J. Exp. Med., November 26, 2001; 194(11): 1549 - 1560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Cervenak, L. Morbidelli, D. Donati, S. Donnini, T. Kambayashi, J. L. Wilson, H. Axelson, E. Castanos-Velez, H.-G. Ljunggren, R. D. W. Malefyt, et al. Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10 Blood, October 1, 2000; 96(7): 2568 - 2573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Guttinger, F. Guidi, M. Chinol, E. Reali, F. Veglia, G. Viale, G. Paganelli, A. Corti, and A. G. Siccardi Adoptive Immunotherapy by Avidin-driven Cytotoxic T Lymphocyte- Tumor Bridging Cancer Res., August 1, 2000; 60(15): 4211 - 4215. [Abstract] [Full Text]
|
|
|
|
|
|
S. Sharma, M. Stolina, Y. Lin, B. Gardner, P. W. Miller, M. Kronenberg, and S. M. Dubinett T Cell-Derived IL-10 Promotes Lung Cancer Growth by Suppressing Both T Cell and APC Function J. Immunol., November 1, 1999; 163(9): 5020 - 5028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Redpath, A. Angulo, N. R. J. Gascoigne, and P. Ghazal Murine Cytomegalovirus Infection Down-Regulates MHC Class II Expression on Macrophages by Induction of IL-10 J. Immunol., June 1, 1999; 162(11): 6701 - 6707. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
